The nitric oxide-guanylate cyclase pathway and glaucoma

Area of Science:

• Ophthalmology
• Neuroscience
• Pharmacology

Background:

• Glaucoma is an optic neuropathy causing irreversible vision loss, with elevated intraocular pressure (IOP) as a primary risk factor.
• Many glaucoma patients progress despite normal IOP, indicating other contributing factors.
• Nitric oxide (NO) regulates IOP and ocular blood flow, and its pathway dysfunction is linked to glaucoma.

Purpose of the Study:

• To review evidence supporting direct targeting of the NO-Guanylate Cyclase (GC) pathway for glaucoma treatment.
• To explore the therapeutic potential of GC activation for IOP regulation and neuroprotection.
• To discuss alternative therapeutic strategies beyond IOP reduction for glaucoma.

Main Methods:

• Review of existing scientific literature on nitric oxide, GC-cGMP pathway, and glaucoma.
• Analysis of NO's multifaceted effects in the eye, including IOP reduction, increased ocular blood flow, and neuroprotection.
• Evaluation of GC-cGMP pathway activation as a therapeutic target.

Main Results:

• NO's effects in the eye are mediated by the GC-cGMP pathway, influencing downstream targets.
• Direct GC targeting offers a novel therapeutic approach for glaucoma, potentially bypassing limitations of NO donors.
• Targeting GC may provide pleiotropic benefits, including neuroprotection and IOP management.

Conclusions:

• Directly targeting the GC pathway presents a promising therapeutic strategy for glaucoma.
• This approach may offer neuroprotective benefits and manage IOP without direct NO application.
• Further research into non-IOP-dependent factors is crucial for comprehensive glaucoma management.